Caleffi M, Fentiman I S, Clark G M, Wang D Y, Needham J, Clark K, La Ville A, Lewis B
Clinical Oncology Unit, United Medical School, Guy's Hospital, London.
J Endocrinol. 1988 Nov;119(2):335-9. doi: 10.1677/joe.0.1190335.
As part of a controlled trial of the use of tamoxifen for the treatment of mastalgia, some of the metabolic and haematological effects of this agent were measured. A panel of haemostatic variables including prothrombin time, kaolin cephalin clotting time, fibrinogen, euglobulin lysis time, factor VII, factor VIII, protein C and anti-thrombin III were determined. In addition, levels of sex hormone-binding globulin and both total and free oestradiol were estimated. No alteration in clotting function was found during the administration of tamoxifen, although hepatic function did alter during this period with an increase in concentration of sex hormone-binding globulin. There was a significant increase in total oestradiol and free oestradiol although the percentage of biologically available free oestradiol fell slightly during the course of tamoxifen treatment. There was a slight reduction in low-density lipoprotein cholesterol with an increase in HDL2, a subclass of high-density lipoprotein (HDL) cholesterol, consistent with an oestrogen-agonist effect. These data suggest that tamoxifen administration does not adversely influence haemostatic mechanisms or lipoprotein metabolism in the short term.
作为他莫昔芬治疗乳腺疼痛对照试验的一部分，对该药物的一些代谢和血液学效应进行了测定。测定了一组止血变量，包括凝血酶原时间、高岭土部分凝血活酶时间、纤维蛋白原、优球蛋白溶解时间、因子VII、因子VIII、蛋白C和抗凝血酶III。此外，还估计了性激素结合球蛋白以及总雌二醇和游离雌二醇的水平。在服用他莫昔芬期间未发现凝血功能改变，尽管在此期间肝功能发生了变化，性激素结合球蛋白浓度升高。总雌二醇和游离雌二醇显著增加，尽管在他莫昔芬治疗过程中生物可利用的游离雌二醇百分比略有下降。低密度脂蛋白胆固醇略有降低，高密度脂蛋白（HDL）胆固醇的一个亚类HDL2增加，这与雌激素激动剂效应一致。这些数据表明，短期内服用他莫昔芬不会对止血机制或脂蛋白代谢产生不利影响。
